1.Marrian, G & Haslewood, G (1932) Equol, a new inactive phenol isolated from the ketohydroxyoestrin fraction of mare's urine. Biochem J 26, 1227–1232.
2.Axelson, M, Kirk, DN, Farrant, RD et al. . (1982) The identification of the weak oestrogen equol [7-hydroxy-3-(4’-hydroxyphenyl)chroman] in human urine. Biochem J 201, 353–357.
3.Bennetts, HW, Underwood, EJ & Shier, FL (1946) A specific breeding problem of sheep on subterranean clover pastures in Western Australia. Aust J Agric Res 22, 131–138.
4.Shutt, DA (1976) The effects of plant oestrogens on animal reproduction. Endeavour 35, 110–113.
5.Messina, M, Nagata, C & Wu, AH (2006) Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 55, 1–12.
6.Setchell, KDR, Brown, NM & Lydeking-Olsen, E (2002) The clinical importance of the metabolite equol – a clue to the effectiveness of soy and its isoflavones. J Nutr 132, 3577–3584.
7.Yuan, J-P, Wang, J-H & Liu, X (2007) Metabolism of dietary soy isoflavones to equol by human intestinal microflora – implications for health. Mol Nutr Food Res 51, 765–781.
8.Lampe, JW (2009) Is equol the key to the efficacy of soy foods? Am J Clin Nutr 89, 1664S–1667S.
9.Bowey, E, Adlercreutz, H & Rowland, I (2003) Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. Food Chem Toxicol 41, 631–636.
10.Setchell, K, Zimmer-Nechemias, L, Cai, J et al. . (1997) Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet 350, 23–27.
11.Setchell, K, Zimmer-Nechemias, L, Cai, J et al. . (1998) Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Am J Clin Nutr 68, 1453S–1461S.
12.Hoey, L, Rowland, I, Lloyd, A et al. . (2004) Influence of soya-based infant formula consumption on isoflavone and gut microflora metabolite concentrations in urine and on faecal microflora composition and metabolic activity in infants and children. Br J Nutr 91, 607–616.
13.Brown, NM, Belles, CA, Lindley, SL et al. . (2010) The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis 31, 886–893.
14.Setchell, KDR, Clerici, C, Lephart, E et al. . (2005) S-equol, a potent ligand for estrogen receptor b, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 81, 1072–1079.
15.Lampe, JW, Karr, SC, Hutchins, AM et al. . (1998) Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 217, 335–339.
16.Rowland, I, Wiseman, H, Sanders, TAB et al. . (2000) Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 36, 27–32.
17.Setchell, KDR & Cole, SJ (2006) Method of defining equol-producer status and its frequency among vegetarians. J Nutr 136, 2188–2193.
18.Tanaka, M, Fujimoto, K, Chihara, Y et al. . (2009) Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers. Prostate Cancer Prostatic Dis 12, 247–252.
19.Liu, B, Liu, A, Uchiyama, S et al. . (2010) Prevalence of equol producer phenotype and its relations to lifestyle factors and dietary intakes among lifestyle factors and dietary intakes among healthy Chinese adults in Beijing. Wei Sheng Yan Jiu 39, 59–64.
20.Ueno, T & Uchiyama, S (2001) Identification of the specific intestinal bacteria capable of metabolising soy isoflavone to equol. Ann Nutr Metab 45, 114.
21.Yee, S, Burdock, GA, Kurata, Y et al. . (2008) Acute and subchronic toxicity and genotoxicity of SE5-OH, an equol-rich product produced by Lactococcus garvieae. Food Chem Toxicol 46, 2713–2720.
22.Hedlund, TE, Maroni, PD, Ferucci, PG et al. . (2005) Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in Caucasian men. J Nutr 135, 1400–1406.
23.Bolca, S, Possemiers, S, Herregat, A et al. . (2007) Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. J Nutr 137, 2242–2246.
24.McMullen, MH, Hamilton-Reeves, JM, Bonorden, MJ et al. . (2006) Consumption of Lactobacillus acidophilus and Bifidobacterium longum does not alter phytoestrogen metabolism and plasma hormones in men: a pilot study. J Altern Complement Med 12, 887–894.
25.Larkin, TA, Price, WE & Astheimer, LB (2007) Increased probiotic yogurt or resistant starch intake does not affect isoflavone bioavailability in subjects consuming a high soy diet. Nutrition 23, 709–718.
26.Larkin, TA, Astheimer, LB & Price, WE (2007) Dietary combination of soy with a probiotic or prebiotic food significantly reduces total and LDL cholesterol in mildly hypercholesterolaemic subjects. Eur J Clin Nutr 63, 238–245.
27.Frankenfeld, CL, Atkinson, C, Thomas, WK et al. . (2004) Familial correlations, segregation analysis, and nongenetic correlates of soy isoflavone-metabolizing phenotypes. Exp Biol Med 229, 902–913.
28.Frankenfeld, CL, Atkinson, C, Thomas, WK et al. . (2005) High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart. Br J Nutr 94, 873–876.
29.Adlercreutz, H, Bowey, E, Heinonen, SM et al. . (2004) Role of the intestine in the production of equol. J Nutr 134, 1234S.
30.Nagel, S, vom Saal, F & Welshons, W (1998) The effective free fraction of estradiol and xenoestrogens in human serum measured by whole cell uptake assays: physiology of delivery modifies estrogenic activity. Proc Soc Exp Biol Med 217, 300–309.
31.Hodgson, J, Croft, K, Puddey, I et al. . (1996) Soybean isoflavonoids and their metabolic products inhibit in vitro lipoprotein oxidation in serum. J Nutr Biochem 7, 664–669.
32.Mitchell, J, Gardner, P, McPhail, D et al. . (1998) Antioxidant efficacy of phytoestrogens in chemical and biological model systems. Arch Biochem Biophys 360, 142–148.
33.Arora, A, Nair, M & Strasburg, G (1998) Antioxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch Biochem Biophys 356, 133–141.
34.Lund, T, Munson, D, Haldy, M et al. . (2004) Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod 70, 1188–1195.
35.Martin, M, Haourigui, M, Pelissero, C et al. . (1996) Interactions between phytoestrogens and human sex steroid binding protein. Life Sci 58, 429–436.
36.World Cancer Research Fund/American Institute for Cancer Research (2007) Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR.
37.Ferlay, J, Shin, HR, Bray, F et al. (2008) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; available at http://globocan.iarc.fr (accessed June 2010).
38.Setchell, KDR & Adlercreutz, H (1988) Mammalian lignans and phyto-oestrogens. Recent studies on their formation, metabolism and biological role in health and disease. In Role of the Gut Flora in Toxicity and Cancer, pp. 315–345 [Rowland, I]. London: Academic Press.
39.Adlercreutz, H, Fotsis, T, Heikkinen, R et al. . (1982) Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian women and in women with breast cancer. Lancet 2, 1295–1299.
40.Adlercreutz, H, Hockerstedt, K, Bannwart, C et al. (1988) Association between dietary fiber, urinary excretion of lignans and isoflavonic phytoestrogens, and plasma non-protein bound sex hormones in relation to breast cancer. In Progress in Cancer Research Therarpy, Vol 35: Hormones and Cancer 3, pp. 409–412 [Bresciani, F, King, R, Lippman, M and Raynaud, J-P, editors]. New York: Raven Press.
41.Adlercreutz, H, Fotsis, T, Bannwart, C et al. . (1986) Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem 25, 791–797.
42.Adlercreutz, H, Hockerstedt, K, Bannwart, C et al. . (1987) Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). J Steroid Biochem 27, 1135–1144.
43.Adlercreutz, H, Honjo, H & Higashi, A (1991) Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming traditional Japanese diet. Am J Clin Nutr 54, 1093–1100.
44.Adlercreutz, H, Hamalainen, E, Gorbach, S et al. . (1992) Dietary phyto-oestrogens and the menopause in Japan. Lancet 339, 1233.
45.Adlercreutz, H, Markkanen, H & Watanabe, S (1993) Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342, 1209–1210.
46.Adlercreutz, H, Goldin, B, Gorbach, S et al. . (1995) Soybean phytoestrogen intake and cancer risk. J Nutr 125, 757S–770S.
47.Ingram, D, Sanders, K, Kolybaba, M et al. . (1997) Case-control study of phyto-oestrogens and breast cancer. Lancet 350, 990–994.
48.Goodman, MT, Shvetsov, YB, Wilkens, LR et al. . (2009) Urinary phytoestrogen excretion and postmenopausal breast cancer risk: The Multiethnic Cohort Study. Cancer Prev Res 2, 887–894.
49.Grace, PB, Taylor, JL, Low, Y-L et al. . (2004) Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European Prospective Investigation of Cancer and Nutrition – Norfolk. Cancer Epidemiol Biomarkers Prev 13, 698–708.
50.Ward, H, Chapelais, G, Kuhnle, GGC et al. . (2008) Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European Prospective into Cancer-Norfolk cohort study. Breast Cancer Res 10:R32.
51.Messina, M (2010) A brief historical overview of the past two decades of soy and isoflavone research. J Nutr 140, 1350S–1354S.
52.Duncan, AM, Merz-Demlow, BE, Xu, X et al. . (2000) Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9, 581–586.
53.Nettleton, JA, Greany, KA, Thomas, W et al. . (2005) The effect of soy consumption on the urinary 2:16-hydroxyestrone ratio in postmenopausal women depends on equol production status but is not influenced by probiotic consumption. J Nutr 135, 603–608.
54.Kabat, GC, Chang, CJ, Sparano, JA et al. . (1997) Urinary estrogen metabolites and breast cancer: a case control study. Cancer Epidemiol Biomarkers Prev 6, 505–509.
55.Muti, P, Bradlow, HL, Micheli, A et al. . (2000) Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11, 635–640.
56.Fishman, J, Schneider, J, Hershcope, RJ et al. . (1984) Increased estrogen-16 alpha-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem 20, 1077–1081.
57.Ursin, G, London, S, Stanczyk, FZ et al. . (1999) Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91, 1067–1072.
58.Adlercreutz, H, Fotsis, T, Hockerstedt, K et al. . (1989) Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. J Steroid Biochem 34, 527–530.
59.Frankenfeld, CL, McTiernan, A, Aiello, EJ et al. . (2004) Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Cancer Epidemiol Biomarkers Prev 13, 1156–1162.
60.Fuhrman, BJ, Teter, BE, Barba, M et al. . (2008) Equol status modifies the association of soy intake and mammographic density in a sample of postmenopausal women. Cancer Epidemiol Biomarkers Prev 17, 33–42.
61.Atkinson, C, Newton, KM, Aiello Bowles, EJ et al. . (2009) Daidzein-metabolizing phenotypes in relation to mammographic breast density among premenopausal women in the United States. Breast Cancer Res Treat 116, 587–594.
62.Magee, PJ & Rowland, IR (2004) Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91, 513–531.
63.Zava, DT, Blen, M & Duwe, G (1997) Estrogenic activity of natural and synthetic estrogens in human breast cancer cells in culture. Environ Health Perspect 105, 637–645.
64.Schmitt, E, Dekant, W & Stopper, H (2001) Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro 15, 433–439.
65.Magee, PJ, Raschke, M, Steiner, C et al. . (2006) Equol: a comparison of the effects of the racemic compound with that of the purified S-enantiomer on the growth, invasion, and DNA integrity of breast and prostate cells in vitro. Nutr Cancer 54, 232–242.
66.Messina, M & Wu, AH (2009) Perspectives on the soy-breast cancer relation. Am J Clin Nutr 89, 1673S–1679S.
67.Akaza, H, Miyanaga, N, Takashima, N et al. . (2004) Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 34, 86–89.
68.Ozasa, K, Nakao, M, Watanabe, Y et al. . (2004) Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 95, 65–71.
69.Hedlund, TE, Johannes, WU & Miller, GJ (2003) Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 54, 68–78.
70.Mitchell, JH, Duthie, SJ & Collins, AR (2000) Effects of phytoestrogens on growth and DNA integrity in human prostate tumor cell lines: PC-3 and LNCaP. Nutr Cancer 38, 223–228.
71.Morton, MS, Chan, PS, Cheng, C et al. . (1997) Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong and the United Kingdom. Prostate 32, 122–128.
72.Gardner, CD, Oelrich, B, Liu, JP et al. . (2009) Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Prostate 69, 719–726.
74.Lichtenstein, AH (1998) Soy protein, isoflavones and cardiovascular disease risk. J Nutr 128, 1589–1592.
75.Nagata, C (2000) Ecological study of the association between soy product intake and mortality from cancer and heart disease in Japan. Int J Epidemiol 29, 832–836.
76.Food and Drug Administration (1999) Food Labeling: Health Claims, Soy protein and Coronary Heart Disease. Fed Register 64, 57699–57733.
77.Sacks, FM, Lichtenstein, AH, Van Horn, L et al. . (2006) Soy protein, isoflavones and cardiovascular health. An American Heart Association science advisory for professionals from the nutrition committee. Circulation 113, 1034–1044.
78.Balk, E, Chung, M, Chew, P et al. (2005) Effects of soy on health outcomes. Evidence report/technology assessment No. 126 (prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022). AHRQ Publication No. 05-E024–2. Rockville, MD: Agency for Healthcare Research and Quality.
79.Zhan, S & Ho, SC (2005) Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 81, 397–408.
80.Taku, K, Umegaki, K, Sato, Y et al. . (2007) Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 85, 1148–1156.
81.Anderson, JW, Johnstone, BM & Cook-Newell, ME (1995) Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333, 276–282.
82.EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2009). Scientific opinion on the substantiation of a health claim related to soy protein and reduction of blood cholesterol concentrations pursuant to Article 14 of the Regulation (EC) No 1924/2006. EFSA J 8(7):1688.
83.Meyer, BJ, Larkin, TA, Owen, AJ et al. . (2004) Limited lipid-lowering effects of regular consumption of whole soybean foods. Ann Nutr Metab 48, 67–78.
84.Hall, WL, Vafeiadou, K, Hallund, J et al. . (2006) Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production. Am J Clin Nutr 83, 592–600.
85.Kreijkamp-Kaspers, S, Kok, L, Bots, ML et al. . (2005) Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women. Am J Clin Nutr 81, 189–195.
86.Guo, K, Zhang, B, Chen, C et al. . (2010) Daidzein-metabolising phenotypes in relation to serum lipids and uric acid in adults in Guangzhou, China. Br J Nutr 8, 1–7.
87.Ma, D-F, Qin, L-Q, Wang, P-Y et al. . (2008) Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. Eur J Clin Nutr 62, 155–161.
88.EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2009). Scientific opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 7(9):1270.
89.Lydeking-Olsen, E, Beck-Jensen, J-E, Setchell, KDR et al. . (2004) Soymilk or progesterone for prevention of bone loss. A 2 year randomized, placebo-controlled trial. Eur J Nutr 43, 246–257.
90.Frankenfeld, CL, McTiernan, A, Thomas, WK et al. . (2006) Postmenopausal bone mineral density in relation to soy isoflavone-metabolizing phenotypes. Maturitas 53, 315–324.
91.Kurzer, MS (2008). Soy consumption for reduction of menopausal symptoms. Inflammopharmacology 16, 227–229.
92.Uchyama, S, Ueno, T & Shirota, T (2001) The relationship between soy isoflavones and the menopausal symptoms in Japanese perimenopausal women. Ann Nutr Metab 45, 113.
93.Ishiwata, N, Melby, MK, Mizuno, S et al. . (2009) New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause 16, 141–148.
94.Aso, T (2010) Equol improves menopausal symptoms in Japanese women. J Nutr 140, 1386S–1389S.
95.Matulka, RA, Matsuura, I, Uesugi, T et al. . (2009) Developmental and reproductive effects of SE5-OH: an equol-rich soy-based ingredient. J Toxicol ID: 307618, [Epub 15 December 2008].
96.Setchell, KDR, Zhao, X, Shoaf, SE et al. . (2009) The pharmacokinetics of S-(-)equol administered as SE5-OH tablets to healthy postmenopausal women. J Nutr 139, 2037–2043.